Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors
TipRanks (Tue, 19-May 12:32 PM ET)
Value or Growth? These 20 stocks offer both as markets hover near record highs
Seeking Alpha News (Tue, 19-May 9:44 AM ET)
PRNewswire (Mon, 18-May 4:05 PM ET)
Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio
TipRanks (Mon, 18-May 10:01 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Mon, 18-May 9:30 AM ET)
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
PRNewswire (Mon, 18-May 8:47 AM ET)
4basebio Announces Appointment of Chief Financial Officer and Board Changes
Globe Newswire (Thu, 14-May 7:00 AM ET)
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
PRNewswire (Tue, 5-May 4:01 PM ET)
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
PRNewswire (Tue, 5-May 9:00 AM ET)
PRNewswire (Mon, 4-May 8:30 AM ET)
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Neurocrine Biosciences trades on the NASDAQ stock market under the symbol NBIX.
As of May 21, 2026, NBIX stock price climbed to $155.50 with 923,781 million shares trading.
NBIX has a beta of 0.73, meaning it tends to be less sensitive to market movements. NBIX has a correlation of 0.11 to the broad based SPY ETF.
NBIX has a market cap of $15.64 billion. This is considered a Large Cap stock.
Last quarter Neurocrine Biosciences reported $814 million in Revenue and $1.94 earnings per share. This beat revenue expectation by $51 million and exceeded earnings estimates by $.33.
In the last 3 years, NBIX traded as high as $162.39 and as low as $84.23.
The top ETF exchange traded funds that NBIX belongs to (by Net Assets): IJH, VTI, VB, VBK, VXF.
NBIX has underperformed the market in the last year with a return of +26.5%, while SPY returned +26.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in NBIX shares. However, NBIX has outperformed the market in the last 3 month and 2 week periods, returning +20.9% and +5.8%, while SPY returned +8.0% and +1.2%, respectively. This indicates NBIX has been having a stronger performance recently.
NBIX support price is $151.93 and resistance is $157.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NBIX shares will trade within this expected range on the day.